EP3723761A2 - Forme pharmaceutique orale solide comprenant de la linagliptine - Google Patents

Forme pharmaceutique orale solide comprenant de la linagliptine

Info

Publication number
EP3723761A2
EP3723761A2 EP18914956.0A EP18914956A EP3723761A2 EP 3723761 A2 EP3723761 A2 EP 3723761A2 EP 18914956 A EP18914956 A EP 18914956A EP 3723761 A2 EP3723761 A2 EP 3723761A2
Authority
EP
European Patent Office
Prior art keywords
dosage form
oral dosage
solid oral
weight
form according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18914956.0A
Other languages
German (de)
English (en)
Other versions
EP3723761A4 (fr
Inventor
Ali TÜRKYILMAZ
Nur PEHLIVAN AKALIN
Merve ERGUN DONMEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP3723761A2 publication Critical patent/EP3723761A2/fr
Publication of EP3723761A4 publication Critical patent/EP3723761A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to a solid oral dosage form comprising linagliptin and at least one binder.
  • Linagliptin is used for type 2 or non-insulin dependent diabetes. It is a selective, orally administered, xanthine based dipeptidyl peptidase-4 (DPP-4) inhibitor used as an adjunct to diet and exercise to improve glycemic control. DPP-4 inhibitors work by blocking the action of DPP-4, an enzyme which destroys the hormone incretin.
  • DPP-4 inhibitors work by blocking the action of DPP-4, an enzyme which destroys the hormone incretin.
  • DPP-4 inhibitors work by blocking the action of DPP-4, an enzyme which destroys the hormone incretin.
  • GLP-1 glucagon-like peptide-1
  • GIP glucose-dependent insulinotropic peptide
  • Linagliptin works by binding to DPP-4 and preventing it from breaking down the GLP-1 and GIP. This increases the levels of these hormones in the body and so increases their effect on controlling blood sugar.
  • linagliptin 8-[(3R)-3-aminopiperidin-1 -yl]-7-but-2-yn-1 -yl)-3-methyl-1 - [(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1 H-purine-2,6-dione and its chemical structure is shown in the Formula I.
  • WO2014/026939 patent application discloses a pharmaceutical composition comprising linagliptin or salts thereof with mannitol, copovidone, and magnesium stearate, a process for the preparation of the pharmaceutical composition.
  • a pharmaceutical composition comprising linagliptin or salts thereof with mannitol, copovidone, and magnesium stearate, a process for the preparation of the pharmaceutical composition.
  • mannitol, copovidone, and magnesium stearate a process for the preparation of the pharmaceutical composition.
  • the main object of the present invention is to provide high stability of linagliptin and a long shelf life by the help of selection of excipients in a certain ratio.
  • Another aim of the present invention is to provide a pharmaceutical dosage form comprising linagliptin which has a long shelf life, a short disintegration time, desired dissolution properties and enables a high bioavailability of linaglitpin in a patient.
  • linagliptin refers to not only linagliptin, but also its other pharmaceutically acceptable salt, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs and pharmaceutically acceptable prodrugs thereof.
  • the linagliptin is present as amorphous linagliptin, crystalline linagliptin having polymorphic form A, crystalline linagliptin having polymorphic form B and/or crystalline linagliptin having polymorphic form C or mixtures thereof.
  • the linagliptin is present as a mixture of crystalline linagliptin having polymorphic form A and crystalline linagliptin having polymorphic form B.
  • the pharmaceutical solid oral dosage form comprises linagliptin as an active agent and at least one binder in which the weight ratio of linagliptin to binder is between 0.1 and 6.0. This ratio is important in order to providing high stability of linagliptin and improved flow properties.
  • the weight ratio of linagliptin to binder is between 0.3 and 3.0 or between 0.5 and 2.0.
  • the amount of linagliptin in the composition is between 1 .0% and 10.0% by weight, preferably it is between 2.0% and 7.0%, more preferably it is between 2.5% and 6.0%.
  • particle size means the cumulative volume size distrubition as tested by any conventionally accepted method such as the laser diffraction method (i.e. Malvern Mastersizer 2000 analysis).
  • d (0.9) means the size at which %90 by volume of the particles are finer.
  • linagliptin has a d (0.9) particle size less than 100 pm, preferably linagliptin has a d (0.9) particle size less than 50 pm. This property provides improved flow properties.
  • Suitable binders are selected from the group comprising povidone, copovidone, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, mannitol, gelatin, pullulan, sodium alginate or mixtures thereof.
  • the present invention comprises one or more binders in an amount of from about 1% to about 20% by weight of the composition.
  • DPP-4 inhibitors are not very stable compounds.
  • amine group containing DPP-4 inhibitors like linagliptin may react with many excipients or impurities of excipients.
  • binder ensures high stability of linagliptin in a solid oral dosage composition.
  • povidone is used as binder in the present invention. Povidone has also disintegration property and it is used to enhance dissolution of poorly soluble drugs from solid-dosage forms.
  • binder is povidone and the amount of povidone in the composition is 1.0% and 5.0% by weight.
  • the pharmaceutical acceptable excipients used in the present invention are selected from the group consisting of fillers, disintegrants, lubricants, and film coating agents.
  • Suitable fillers are selected from the group comprising microcrystalline cellulose, mannitol, spray-dried mannitol, lactose, lactose monohydrate, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
  • microcrystalline cellulose is a filler which has the best flowability properties among the other fillers. In this invention, it further improves the disintegration of compositon as well as being a filler. In addition, it further enhances the compressibility by increasing the hardness of the tablet.
  • the amount of microcrystalline cellulose is in the range of 70.0 to 90 %, preferably 76.0 to 88.0 %, more preferably it is 80.0 to 85.0 % by weight of total composition.
  • Suitable disintegrants are selected from the group comprising sodium starch glycolate, cross- linked polyvinil pyrrolidone (crospovidone), povidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, pregelatinized starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, low substituted hydroxypropyl cellulose, polyacryline potassium, sodium alginate, corn starch, alginic acid, alginates, sodium dodecyl sulphate, sodium glycine carbonate, sodium lauryl sulphate or mixtures thereof.
  • crospovidone cross- linked polyvinil pyrrolidone
  • povidone povidone
  • croscarmellose sodium low-substituted hydroxypropyl cellulose
  • pregelatinized starch sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, gu
  • disintegrant that is neither too much nor too little to detrimentally alter the release of the active ingredient should be used to form solid oral dosage forms provided herein.
  • disintegrants can be mixed with other excipient to increase effective disintegration of the tablet into smaller fragments.
  • disintegrant is sodium starch glycolate, is also known as superdisintegrant, and the amount of sodium starch glycolate is in the range of 3.0% to 8.0% and thus desired level of dissolution rate is provided.
  • povidone and sodium starch glycolate provides desired short disintegration time and desired dissolution properties in composition.
  • the weight ratio of sodium starch glycolate to povidone is between 0.2 and 10.0 or 0.6 and 8.0.
  • the lubricant is selected from the group comprising sodium stearyl fumarate, magnesium stearate, polyethylene glycol (PEG), sodium lauryl sulphate, magnesium lauryl sulphate, fumaric acid, glyceryl palmitostearate, hydrogenated natural oils, zinc stearate, calcium stearate, silica, talc, stearic acid, paraffin or mixtures thereof, preferably sodium stearyl fumarate. Coating may also preferably be used for moisture protection.
  • Suitable coating agents are selected from the group comprising polymethacrylates, hydroxypropyl methylcellulose, lactose monohydrate, hydroxypropyl cellulose, polyvinyl alcohol (PVA), polyethylene glycol (PEG), talc, glycerine, polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat® IR), ethylcellulose dispersions (Surelease®), polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA), all kinds of Opadry®, pigments, dyes, titanium dioxide, macrogol, coloring agent or mixtures thereof.
  • Suitable coloring agents are selected from the group comprising ferric oxide, titanium dioxide, Food, Drug & Cosmetic (FD&C) dyes (such as; FD&C blue, FD&C green, FD&C red, FD&C yellow, FD&C lakes), ponceau, indigo Drug & Cosmetic (D&C) blue, indigotine FD&C blue, carmoisine indigotine (indigo Carmine); iron oxides (such as; iron oxide red, yellow, black), quinoline yellow, flaming red, carmine, carmoisine, sunset yellow or mixtures thereof.
  • FD&C Food, Drug & Cosmetic
  • the pharmaceutical composition of the present invention comprises linagliptin or a pharmaceutically acceptable salt thereof, povidone, sodium stearyl fumarate, sodium starch glycolate, microcrystalline cellulose.
  • Solid oral dosage is used for having effective stability and bioavailability.
  • Another embodiment of the present invention is a pharmaceutical composition in the form of a solid oral dosage form.
  • the solid oral dosage form is tablet or capsule or pastilles or strip.
  • the solid oral dosage form is tablet. Tablet may be consisted of separated compartments or layer.
  • the pharmaceutical combination is formulated as tablets comprising film-coated tablets, compressed tablets, coated or uncoated tablets, multilayer tablets, mini tablets, bilayer tablet, pellet in tablet, buccal tablets, sublingual tablets, effervescent tablets, immediate release tablets, core-in-tablet, modified release tablets, tablet-in-tablet, orally disintegrating tablets, gastric disintegrating tablets, chewable tablet, dispersing tablet, lozenges.
  • the pharmaceutical combination is formulated as film coated tablet.
  • the pharmaceutical combination can be prepared in tablet form. Tablet comprises at least one type of particle, for example; mini-tablets, pellets, agglomerates, granules, powders, liposomes, sphericles or mixtures thereof.
  • each type of particle comprises at least one active agent.
  • pharmaceutical combination may comprise a film coating if necessary.
  • Capsule comprises of at least one type of particle, for example; mini-capsules, mini-tablets, pellets, agglomerates, granules, powders, liposomes, sphericles or mixtures thereof.
  • the dosage unit form of composition is mini capsules in capsule wherein the mini-capsules comprise at least one active agent.
  • the dosage unit form of composition is mini-tablets in capsule wherein a mini-tablets comprise at least one active agent.
  • the dosage unit form of composition is pellets in capsule wherein pellets comprise at least one active agent.
  • the composition comprises;
  • the composition comprises;
  • the pharmaceutical composition of the present invention can be prepared, using standard techniques and manufacturing processes well known in the art, such as direct compression, wet and dry granulation.
  • the formulation when the formulation is prepared with wet granulation, the formulation has desired stability and desired dissolution rate.
  • Suitable granulation solutions are selected from a group comprising pure water, ethyl alcohol, glycerin, sorbitol, polyethylene glycol, propylene glycol, isopropyl alcohol or mixtures thereof, preferably the granulation solution is pure water.
  • the process for preparation of the pharmaceutical composition comprises the following steps:
  • Example 1 Film coated tablet comprising linagliptin
  • Example 2 Solid oral dosage form comprising linagliptin
  • the process for preparation of the pharmaceutical composition comprises the following steps:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une forme pharmaceutique orale solide comprenant de la linagliptine et au moins un liant.
EP18914956.0A 2017-12-15 2018-12-14 Forme pharmaceutique orale solide comprenant de la linagliptine Pending EP3723761A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/20515A TR201720515A2 (tr) 2017-12-15 2017-12-15 Li̇nagli̇pti̇n i̇çeren bi̇r kati oral dozaj formu
PCT/TR2018/050812 WO2019203755A2 (fr) 2017-12-15 2018-12-14 Forme pharmaceutique orale solide comprenant de la linagliptine

Publications (2)

Publication Number Publication Date
EP3723761A2 true EP3723761A2 (fr) 2020-10-21
EP3723761A4 EP3723761A4 (fr) 2021-06-30

Family

ID=67900883

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18914956.0A Pending EP3723761A4 (fr) 2017-12-15 2018-12-14 Forme pharmaceutique orale solide comprenant de la linagliptine

Country Status (4)

Country Link
EP (1) EP3723761A4 (fr)
CA (1) CA3085455C (fr)
TR (1) TR201720515A2 (fr)
WO (1) WO2019203755A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022173406A1 (fr) * 2021-02-15 2022-08-18 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Procédé pour formulations de linagliptine ou d'un sel pharmaceutiquement acceptable de celle-ci

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32427A (es) * 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
WO2013128379A2 (fr) 2012-02-27 2013-09-06 Dr. Reddy's Laboratories Limited Formes polymorphes cristallines de linagliptine
WO2014056942A1 (fr) * 2012-10-09 2014-04-17 Boehringer Ingelheim International Gmbh Utilisation de matière à fabriquer les comprimés dont on ajuste sélectivement l'humidité dans la production de comprimés mécaniquement stables qui contiennent au moins une substance active formant un hydrate et/ou un adjuvant lié à la stabilité mécanique des comprimés, en particulier des comprimés contenant de l'arginine
WO2014080384A1 (fr) 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Composition pharmaceutique de linagliptine
WO2014080383A1 (fr) * 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Composition pharmaceutique d'inhibiteurs de la dipeptidyl-peptidase-iv (dpp-iv) en association avec d'autres antidiabétiques
CN106138059A (zh) 2015-03-27 2016-11-23 天津汉瑞药业有限公司 一种稳定的利格列汀药物组合物
EP3156048A1 (fr) 2015-10-13 2017-04-19 Galenicum Health S.L. Composition pharmaceutique stable de linagliptine sous forme de comprimé à libération immédiate

Also Published As

Publication number Publication date
WO2019203755A2 (fr) 2019-10-24
CA3085455C (fr) 2022-08-16
CA3085455A1 (fr) 2019-10-24
TR201720515A2 (tr) 2019-07-22
WO2019203755A3 (fr) 2020-01-16
EP3723761A4 (fr) 2021-06-30

Similar Documents

Publication Publication Date Title
US11033552B2 (en) DPP IV inhibitor formulations
US11819577B2 (en) Fixed dose pharmaceutical composition of valsartan and sacubitril
WO2019194773A2 (fr) Combinaison contenant de la linagliptine et de la metformine
WO2014080384A1 (fr) Composition pharmaceutique de linagliptine
EP2468268B1 (fr) Composition de combinaison de vildagliptine et de gliclazide
EP3781135A2 (fr) Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la sitagliptine
WO2017208136A1 (fr) Composition pharmaceutique de co-cristal de dapagliflozine
US20190110994A1 (en) Pharmaceutical composition of dapagliflozin
EP2848242A1 (fr) Formulations orodispersibles de Linagliptin
CA3085455C (fr) Forme pharmaceutique orale solide comprenant de la linagliptine
WO2020009675A2 (fr) Compositoins pharmaceutiques solides d'administration par voie orale comprenant de la linagliptine
EP4019003A1 (fr) Formulations pharmaceutiques de linagliptine
WO2022153330A1 (fr) Compositions pharmaceutiques comprenant de l'acalabrutinib
WO2019132833A1 (fr) Combinaison à libération modifiée comprenant de la linagliptine et de la metformine
WO2022173406A1 (fr) Procédé pour formulations de linagliptine ou d'un sel pharmaceutiquement acceptable de celle-ci
US20120121722A1 (en) Atazanavir formulations
WO2024084496A1 (fr) Compositions pharmaceutiques comprenant du maléate d'acalabrutinib
US20230310327A1 (en) Pharmaceutical compositions comprising ribociclib
WO2005030219A1 (fr) Procede de stabilisation d'un compose diarylvinylene
EP3731931A2 (fr) Formulations à libération modifiée de fésotérodine
CN116490178A (zh) Sglt-2抑制剂与血管紧张素受体阻滞剂的组合物及用途
EP3731823A1 (fr) Préparation pharmaceutique pour administration par voie orale comportant de l'étexilate de dabigatran
EP3354262A1 (fr) Compositions pharmaceutiques de dexlansoprazole à enrobage entérique
EA040745B1 (ru) Фармацевтическая композиция, содержащая два различных активных ингредиента, и способ ее получения
WO2013180676A1 (fr) Nouvelle formulation à libération prolongée

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200714

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210601

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/522 20060101AFI20210526BHEP

Ipc: A61K 47/00 20060101ALI20210526BHEP

Ipc: A61P 3/10 20060101ALI20210526BHEP

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230708

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231108